Diagnosis and Management of Zollinger-Ellison Syndrome

Clinical Presentation and Diagnosis

• Patients with Zollinger-Ellison Syndrome often present with severe peptic ulceration, chronic diarrhea, gastroesophageal reflux disease refractory to standard therapy, weight loss, and epigastric pain lasting years despite acid-suppressive therapy, with diarrhea occurring in approximately 50% at diagnosis and abdominal pain reported in 70% at diagnosis 1
• Renal failure is a common cause of hypergastrinemia that should be ruled out before pursuing ZES diagnosis 1
• The American Gastroenterological Association recommends suspecting ZES in patients presenting with chronic diarrhea, gastroesophageal reflux disease refractory to standard therapy, and weight loss 1

Treatment Options

• The National Comprehensive Cancer Network recommends somatostatin analogs, chemotherapeutic agents, liver-directed therapies, and liver transplantation in selected cases for metastatic/unresectable disease 2
• The European Society for Medical Oncology suggests that chemotherapeutic agents may be used to treat metastatic disease 1
• Metastases develop in 60% of gastrinoma patients, with likelihood correlated to primary tumor size 1
• The American College of Gastroenterology recommends a multidisciplinary approach including surgical and non-surgical therapies for advanced disease 1

Malignant Gastrinomas

Anatomical Distribution and Diagnosis

• The majority of gastrinomas are located in the duodenum, with the remainder typically found in the pancreas 3
• Laboratory diagnosis includes measurement of fasting serum gastrin levels, which should be performed after discontinuing proton pump inhibitors for 1-2 weeks, as recommended by the American Gastroenterological Association 3, 4

Clinical Implications

• All patients with gastrinoma should be considered as candidates for MEN1 syndrome and should undergo appropriate testing, according to the National Institute of Diabetes and Digestive and Kidney Diseases 3, 4

Diagnostic Approach and Management of Zollinger-Ellison Syndrome

Imaging for Localization

• Somatostatin receptor scintigraphy is useful for initial evaluation of suspected gastrinomas, as recommended by the National Comprehensive Cancer Network, with CT and MRI scans being multiphase for optimal detection 5, 6
• The use of Gallium-68 radiotracers with positron emission tomography is currently the standard for tumor localization in patients with Zollinger-Ellison syndrome, according to the National Comprehensive Cancer Network guidelines 5, 6

Diagnostic Approach for Zollinger-Ellison Syndrome

Tumor Localization and Diagnostic Evaluation

• Cross-sectional imaging, including multiphase CT and MRI scans, plays an important role in diagnosing pancreatic disease and detecting gastrinomas, with the majority of gastrinomas located in the duodenum or pancreas 7
• Endoscopic ultrasound (EUS) and esophagogastroduodenoscopy (EGD) are used for duodenal and gastric evaluation in patients with suspected Zollinger-Ellison syndrome, as recommended by the National Comprehensive Cancer Network 8
• Endoscopy should be performed to assess for peptic ulcer disease and esophagitis in patients with Zollinger-Ellison syndrome, according to the National Comprehensive Cancer Network 9

Diagnostic Pitfalls

• A therapeutic trial of pancreatic enzymes should not be relied upon for diagnosis of Zollinger-Ellison syndrome, as it is unreliable, as noted in Gastroenterology 7

Management of Zollinger-Ellison Syndrome with Somatostatin Analogues

Medical Management of Metastatic/Unresectable Disease

• The European Society for Medical Oncology recommends somatostatin analogues, such as lanreotide autogel 60-120 mg/month or octreotide LAR 10-30 mg/month, as primary antiproliferative therapy for metastatic or unresectable disease, with liver-directed therapies including radiofrequency ablation, UAE, TACE, and SIRT as options for hepatic metastases 10
• Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE may be considered for progressive disease to improve symptoms, and everolimus can be used off-label for uncontrolled symptoms in refractory cases with progressive disease, though not approved by EMA or FDA for this indication 10
• Liver transplantation may be considered in early therapy failure in young adults with high tumor burden, stable liver-only disease, and the American College of Gastroenterology recommends a multidisciplinary approach including both surgical and non-surgical therapies for advanced disease, with careful observation required for acute aggravation of symptoms during or after PRRT 10

Zollinger-Ellison Syndrome Diagnosis and Characteristics

Diagnostic Approach and Tumor Localization

• Gastrinomas are subepithelial neuroendocrine tumors that arise from deeper layers, making standard mucosal biopsies non-diagnostic, and are typically located in the duodenum or pancreas within the "gastrinoma triangle" 11, 12
• The National Comprehensive Cancer Network recommends the use of endoscopic ultrasound (EUS) for tumor localization, particularly for pancreatic gastrinomas, with a sensitivity of up to 83% 13, 14

Tumor Characteristics and Clinical Presentation

• Gastrinomas are submucosal lesions covered by normal-appearing epithelium, and their diagnosis is based on biochemical testing, including fasting serum gastrin levels and gastric acid hypersecretion 11, 12

Diagnostic Approach for Zollinger-Ellison Syndrome

Initial Management

• The American Gastroenterological Association recommends high-dose PPIs as the initial treatment of choice for confirmed Zollinger-Ellison syndrome, with a starting dose of omeprazole at 60 mg/day 15

Diagnostic Blood Tests

• The National Institute of Diabetes and Digestive and Kidney Diseases suggests that serum chromogranin A (CgA) levels should be measured after stopping PPIs for at least 14 days to avoid false positive results 15
• The Endocrine Society recommends measuring serum calcium and parathyroid hormone to screen for Multiple Endocrine Neoplasia Type 1 (MEN-1) in all gastrinoma patients 15